Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Proteomics International Laboratories Ltd. ( (AU:PIQ) ).
Proteomics International Laboratories Ltd has successfully completed a $12 million capital raise to accelerate the launch of its diagnostic tests, including the Promarker®D test for diabetic kidney disease, which has been launched in the USA and Australia. The company is also advancing other diagnostic tests such as Promarker®Eso for esophageal cancer and Promarker®Endo for endometriosis, with significant progress in clinical validation and market readiness. The strategic expansion of its precision diagnostics capability, supported by a $6 million funding boost, positions the company to capitalize on the growing telehealth market and potential partnerships in the diagnostics sector.
The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.43 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
More about Proteomics International Laboratories Ltd.
Proteomics International Laboratories Ltd is a leader in precision diagnostics and precision medicine, specializing in the development of novel diagnostic tests using its proprietary Promarker® biomarker discovery platform. The company focuses on commercializing precision diagnostic tests, advancing tests in development, and providing specialist analytical services. Its market strategy includes leveraging the growing telehealth sector and consumer demand for preventative care.
Average Trading Volume: 332,507
Technical Sentiment Signal: Sell
Current Market Cap: A$64.65M
Learn more about PIQ stock on TipRanks’ Stock Analysis page.